FEMY
HEALTHCAREFemasys Inc
AI Insight
What's Moving FEMY Today?
No stock-specific AI insight has been generated for FEMY yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.77$22.20
$4.01
Fundamentals
Market Cap$12M
P/E Ratio—
EPS$-4.78
Dividend Yield—
Dividend / Share—
ROE-256.0%
Profit Margin—
Debt / Equity—
Trading
Volume13K
Avg Volume (10D)—
Shares Outstanding3.0M
FEMY News
23 articles- Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million MoreMotley Fool·May 29, 2026
- Femasys (NASDAQ: FEMY) outlines FemaSeed fertility and FemBloc birth control strategyStock Titan·May 14, 2026
- Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ CatheterYahoo Finance·May 13, 2026
- Net income returns at Femasys (NASDAQ: FEMY) as Q1 2026 results filedStock Titan·May 9, 2026
- Femasys starts birth-control trial as it expands fertility careStock Titan·May 9, 2026
- Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate UpdateYahoo Finance·May 8, 2026
- Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® CompleteYahoo Finance·May 5, 2026
- Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026Yahoo Finance·Apr 22, 2026
- Femasys Drives International Growth with Israeli Market Entry for Fertility PortfolioYahoo Finance·Apr 16, 2026
- Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial GrowthYahoo Finance·Apr 1, 2026
- Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate UpdateYahoo Finance·Mar 31, 2026
- Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of DirectorsYahoo Finance·Mar 18, 2026
- Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial EnrollmentYahoo Finance·Mar 10, 2026
- Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Feb 27, 2026
- Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market AccessYahoo Finance·Feb 26, 2026
- Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal InseminationYahoo Finance·Feb 23, 2026
- Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio ProductsYahoo Finance·Feb 3, 2026
- Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RequirementYahoo Finance·Jan 14, 2026
- Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based CareYahoo Finance·Jan 13, 2026
- Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic DeviceYahoo Finance·Dec 18, 2025
- PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital DeploymentYahoo Finance·Nov 25, 2025
- Femasys Announces Third Quarter Financial Results for 2025Yahoo Finance·Nov 14, 2025
- Femasys Advances Global Growth with Second Partner Order for FemBloc® in EuropeYahoo Finance·Nov 10, 2025
All 23 articles loaded
Price Data
Open$4.07
Previous Close$4.08
Day High$4.16
Day Low$4.01
52 Week High$22.20
52 Week Low$3.77
52-Week Range
$3.77$22.20
$4.01
Fundamentals
Market Cap$12M
P/E Ratio—
EPS$-4.78
Dividend Yield—
Dividend / Share—
ROE-256.0%
Profit Margin—
Debt / Equity—
Trading
Volume13K
Avg Volume (10D)—
Shares Outstanding3.0M
About Femasys Inc
Femasys Inc. is a pioneering medical technology company focused on revolutionizing women's healthcare with its proprietary, non-surgical solutions for diagnosing and treating gynecological conditions, including uterine fibroids and contraception. By addressing significant unmet needs in women's health, Femasys is positioned to benefit from the growing demand for minimally invasive treatments, which enhance patient outcomes and improve healthcare efficiency. The company's innovative approach aims to set new standards of care, reinforcing its commitment to transforming the landscape of women's health and solidifying its role as a key player in this vital and expanding market.
HEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICMEDICAL INSTRUMENTS & SUPPLIES
CIK—
Composite FIGI—
Share Class FIGI—